Background. Cytomegalovirus enterocolitis is a rare but potentially life threatening complication after allogeneic stem cell transplantation. Its early diagnosis and treatment are essential for a successful outcome. Objective. To determine the potential benefit of fecal CMV DNA detection in the diagnosis of CMV colitis among stem cell transplant recipients. Study design. Biopsies from the lower gastrointestinal tract, taken during 69 episodes of diarrhea, were compared with fecal samples previously examined for CMV DNA in 45 patients after allogeneic stem cell transplantation. Results. Six confirmed cases of CMV colitis were observed, with 16 out of 69 (23%) fecal samples proving positive for CMV DNA. Only one positive sample correlated with histologically confirmed CMV colitis, and 15 samples were evaluated as false positive. These results provide a 16.7% sensitivity and 76.2% specificity in the diagnosis of CMV enterocolitis. Conclusion. The examination of fecal samples for the presence of CMV DNA has very low potential in the diagnosis of CMV enterocolitis after allogeneic stem cell transplantation; therefore, a biopsy of the gastrointestinal mucosa is still warranted for correct diagnosis.
INTRODUCTION
The transplantation of allogeneic stem cells frequently leads to various gastrointestinal complications that could be the source of major morbidity and mortality among allogeneic transplant recipients. Graft versus host disease (GVHD), infections, and the toxicity of previous treatments are the major cause of gastrointestinal problems in these patients 1, 2 . An early diagnosis, followed by adequate treatment, is the most important prerequisite of any successful therapy. During recent years, several invasive and non-invasive diagnostic methods have been developed, and though their clinical results are available within a very short time their validation in stem cell transplant recipients is still lacking.
Cytomegalovirus (CMV) is a common herpes virus that can become reactivated in an immunocompromised host, especially after stem cell transplantation 3 , causing a wide variety of end organ damage 4 , with pneumonia and enterocolitis being the most common stem cell transplant recipients 5 . The incidence of CMV induced enterocolitis is of ∼2% among transplant recipients, although its diagnosis remains challenging since there is neither a unique clinical picture nor a specific laboratory test 6 . The widely accepted diagnostic criteria is based on clinical symptoms, macroscopic findings through endoscopy, and histological analyses (culture, histopathology, immunohistochemical analysis, or in situ hybridization) (ref. 7 ). Obtaining the biopsies might be complicated in transplant recipients and potentially lead to severe complications 8, 9 . CMV detection by PCR in fecal samples could replace invasive techniques; therefore, the aim of the present study was determine the detection capacity of CMV DNA by PCR in fecal samples.
STUDY DESIGN

Patients and specimens
We performed a retrospective review of all patient's charts, including reports from lower gastrointestinal tract biopsies from patients presenting diarrhea after stem cell transplantation. The evaluation consisted of samples obtained from January 2008 to July 2015, only the peripheral blood and fecal samples from single episode of diarrhea were analyzed by PCR. Since no additional tests were done and this was purely retrospective chart analysis, an informed consent by the patients was not deemed necessary. The clinical data was obtained from patients' charts and independently reviewed by two physicians -AZ and JR.
Histopathology analysis
CMV immunohistochemistry is part of the routine examination of patient's samples. Sections of 2 µm in thickness were stained with hematoxylin/eosin for light microscopy examination. For immunohistochemical analysis, 3µm sections were immunostained using a Ventana autostainer ultraview detection kit (Ventana). Immunohistochemical studies were performed using monoclonal mouse anti -cytomegalovirus, clones CCH2+DDG9 (DAKO Denmark, dilution 1:100).
PCR analysis
CMV viremia was determined by qPCR from peripheral blood. DNA extraction was performed using a QIAamp DNA Mini Kit (Qiagen), quantitative DNA determination by CMV RG PCR (Qiagen) with 500 copies per ml of full peripheral blood (cp/mL) as the quantification cut off, and 100 cp/mL (i.e. 79.4 UI/mL) as the detection cut off. For fecal analysis, viral DNA was extracted from stool samples after dilution and centrifugation using a QIAamp DNA Mini Kit (Qiagen). CMV DNA was detected using the CMV RG PCR kit (Qiagen) in a RotorGene 3000. The detection limit was of 100 copies per sample; however, due to complicated interpretation and extremely variable stool amounts from the patients, the results are reported only as positive or negative.
Definition of CMV enterocolitis case
The diagnosis of CMV colitis was based on positive imunohistochemistry in correlation with clinical and endoscopic features according to previously published recommendations 7 . Graft versus host disease was confirmed by histology; other infectious etiologies were confirmed by specific microbiological sampling as per institutional standards. The toxicity of previous treatments was considered only in cases where other etiologies were excluded by microbiological sampling and non-descriptive histology, and endoscopic features were present.
Statistical analysis
The diagnostic test evaluation was performed using the MedCalc v 9.5.2.0 software (MedCalc Software bvba, Belgium). An unpaired sample t-test was used to compare serum CMV quantities, (P<0.05) was considered statistically significant.
RESULTS
Intestinal tissue, fecal and serum samples were collected from 45 included patients during 69 episodes of Table 2 . Fig. 1 shows positive immunohistochemistry CMV staining and Fig. 2 shows negative results as an example. Sixteen out of sixty-nine (23%) fecal samples were positive for CMV DNA, only 1 of 6 (16.7%) CMV enterocolitis episodes correlated with positive CMV DNA in faeces. Fifteen samples were evaluated as false positive (positive fecal CMV DNA without evidence of CMV colitis). This resulted in 16.7% sensitivity and 76.2% specificity in the diagnosis of CMV enterocolitis by CMV PCR in fecal samples (Table 3) . Twenty-two of sixty-nine (32%) blood samples were positive for DNA CMV, of these 4 samples were positive episodes of CMV enterocolitis. This resulted in 66.7% sensitivity and 71.4% specificity in the diagnosis of CMV enterocolitis ( Table 3 ). The median number of copies per mL in peripheral blood was not statistically significantly different between cases of CMV and non-CMV colitis (530 copies/mL versus 498 copies/mL, respectively; P=0.34).
DISCUSSION
According to current practice guidelines, the diagnosis of CMV enterocolitis requires a gut biopsy 7, 10, 11 . The diagnosis of CMV enterocolitis by CMV DNA detection in peripheral blood or antigenemia testing has yielded conflicting results; although some degree of accuracy has been observed in non-stem cell transplant patients. Durand et al. 12 showed an 85% sensitivity and 95% speci- ficity when diagnosing CMV enterocolitis through plasma PCR testing among kidney and liver transplant patients; further, a strong diagnostic tool has also been found in CMV antigenemia testing 13 . However, the opposite has been found in stem cell transplant recipients, which show limited reliability for these assays. In a study by Mori et al.
14 only 50% of patients with CMV enterocolitis yielded positive results from real-time PCR analysis of blood samples before developing CMV-GI disease. This low reliability might be caused by regular blood testing for CMV DNA and an early start of pre-emptive treatment, which is not the case in non-stem cell transplant recipients. This fact might potentially mimic the reactivation in specific predisposed end organs. In the present study, we have confirmed the low sensitivity and specificity of blood CMV DNA testing in stem cell transplant recipients.
Since molecular methods are being validated for fecal samples in the diagnosis of other types of viral gastroenteritis 15, 16 , we attempted to improve the diagnostic strategy for CMV colitis by detecting DNA CMV in these samples. However, only scarce data has been published suggesting that the detection of DNA CMV in fecal samples might add some value for the differential diagnosis of diarrhea in immunocompromised patients and patients with inflammatory bowel disease (IBD). According to a study by Ganzenmueller et al. 17 , conducted on immunocompromised patients (68% stem cell or solid organ transplantation), the PCR analysis from fecal samples were positive in 8 out of 12 patients with CMV enterocolitis. This data was confirmed by Michel et al. 18 in a study on immunocompromised patients where all 4 patients with CMV enterocolitis were tested positive in the PCR analysis of fecal samples, with only one false positive result. Similar data was published by Herfarth et al. 19 on IBD patients, where the sensitivity and specificity of the PCR analysis in fecal samples diagnosing CMV enterocolitis was 83 and 93%, respectively. However, we could not confirm these results in our study, which was aimed at a unique group of allogeneic stem cell transplant recipients and is one of the largest reported. Further, the correlation of fecal samples with the diagnosis of CMV enterocolitis was very low in our cohort, observing a high rate of false positive hits and even higher false negative results. Moreover, we would have missed 5 CMV enterocolitis cases (83%) had we solely relied on non-invasive techniques; to complicated matters further, we could have been administering the wrong treatment to 15 false positive patients.
Interestingly, GVHD of the gut preceded the development of CMV colitis in 5 of 6 patients, the only patient without precedent of GVHD suffered from IBD, suggesting a strong link with an impaired gut mucosa and further deterioration of the immune status due to GVHD and its treatment. Further, CMV disease might develop as a second hit disease, according to Boeckh et al who showed GVHD as a predictive factor for CMV disease development 20 . As described previously, seropositive patients are at highest risk of CMV disease development 21 and in our study only CMV seropositive patients developed CMV enterocolitis, despite that four of these six patients had seronegative donors.
Our data suggest that a gut biopsy cannot be omitted when regarding CMV colitis because its diagnosis cannot be based only on non-invasive tests. Easily obtainable clinical data, such as CMV serostatus or history of GVHD, could facilitate the identification of patients prone to the development of CMV enterocolitis and thus determine if an invasive sampling is needed. Therefore, endoscopic examination will probably remain the gold standard for the diagnosis of patients after stem cell transplantation without an identifiable cause of diarrhea.
